TELADOC HEALTH INC (TDOC) Stock Fundamental Analysis
NYSE:TDOC - New York Stock Exchange, Inc. - US87918A1051 - Common Stock
TDOC gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 39 industry peers in the Health Care Technology industry. TDOC may be in some trouble as it scores bad on both profitability and health. TDOC is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year TDOC has reported negative net income.
In the past year TDOC had a positive cash flow from operations.
TDOC had negative earnings in each of the past 5 years.
TDOC had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
TDOC has a Return On Assets (-27.82%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -65.11%, TDOC is in line with its industry, outperforming 51.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.82% | ||
| ROE | -65.11% | ||
| ROIC | N/A |
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With a decent Gross Margin value of 70.82%, TDOC is doing good in the industry, outperforming 78.38% of the companies in the same industry.
TDOC's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for TDOC so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.82% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
TDOC does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TDOC has been increased compared to 1 year ago.
Compared to 5 years ago, TDOC has more shares outstanding
The debt/assets ratio for TDOC has been reduced compared to a year ago.
2.2 Solvency
TDOC has an Altman-Z score of -5.18. This is a bad value and indicates that TDOC is not financially healthy and even has some risk of bankruptcy.
TDOC's Altman-Z score of -5.18 is on the low side compared to the rest of the industry. TDOC is outperformed by 70.27% of its industry peers.
The Debt to FCF ratio of TDOC is 7.45, which is on the high side as it means it would take TDOC, 7.45 years of fcf income to pay off all of its debts.
TDOC has a better Debt to FCF ratio (7.45) than 62.16% of its industry peers.
TDOC has a Debt/Equity ratio of 0.66. This is a neutral value indicating TDOC is somewhat dependend on debt financing.
TDOC has a worse Debt to Equity ratio (0.66) than 70.27% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 7.45 | ||
| Altman-Z | -5.18 |
ROIC/WACCN/A
WACC7.43%
2.3 Liquidity
A Current Ratio of 1.73 indicates that TDOC should not have too much problems paying its short term obligations.
The Current ratio of TDOC (1.73) is comparable to the rest of the industry.
A Quick Ratio of 1.69 indicates that TDOC should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.69, TDOC perfoms like the industry average, outperforming 54.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.69 |
3. Growth
3.1 Past
TDOC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.42%, which is quite impressive.
TDOC shows a small growth in Revenue. In the last year, the Revenue has grown by 0.39%.
Measured over the past years, TDOC shows a very strong growth in Revenue. The Revenue has been growing by 44.17% on average per year.
EPS 1Y (TTM)95.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
Revenue 1Y (TTM)0.39%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Sales Q2Q%-2.99%
3.2 Future
The Earnings Per Share is expected to grow by 10.53% on average over the next years. This is quite good.
The Revenue is expected to grow by 1.04% on average over the next years.
EPS Next Y-342.57%
EPS Next 2Y14.84%
EPS Next 3Y10.66%
EPS Next 5Y10.53%
Revenue Next Year-1.69%
Revenue Next 2Y-1.32%
Revenue Next 3Y-0.28%
Revenue Next 5Y1.04%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TDOC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TDOC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of TDOC indicates a rather cheap valuation: TDOC is cheaper than 97.30% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, TDOC is valued cheaper than 89.19% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.56 | ||
| EV/EBITDA | 3.64 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.84%
EPS Next 3Y10.66%
5. Dividend
5.1 Amount
TDOC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TELADOC HEALTH INC
NYSE:TDOC (1/17/2025, 8:04:00 PM)
After market: 9.11 +0.02 (+0.22%)9.09
-0.07 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners83.27%
Inst Owner Change-0.02%
Ins Owners0.46%
Ins Owner Change0.05%
Market Cap1.57B
Analysts68.48
Price Target11.12 (22.33%)
Short Float %13.96%
Short Ratio4.3
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)26.66%
Min EPS beat(2)20.89%
Max EPS beat(2)32.44%
EPS beat(4)3
Avg EPS beat(4)17.89%
Min EPS beat(4)-3.79%
Max EPS beat(4)32.44%
EPS beat(8)6
Avg EPS beat(8)-1139.65%
EPS beat(12)9
Avg EPS beat(12)-984%
EPS beat(16)10
Avg EPS beat(16)-818.13%
Revenue beat(2)0
Avg Revenue beat(2)-1.78%
Min Revenue beat(2)-3.05%
Max Revenue beat(2)-0.51%
Revenue beat(4)0
Avg Revenue beat(4)-1.93%
Min Revenue beat(4)-3.55%
Max Revenue beat(4)-0.51%
Revenue beat(8)0
Avg Revenue beat(8)-1.66%
Revenue beat(12)0
Avg Revenue beat(12)-1.55%
Revenue beat(16)0
Avg Revenue beat(16)-1.47%
PT rev (1m)1.23%
PT rev (3m)9.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-818.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.13%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.98%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.6 | ||
| P/FCF | 7.56 | ||
| P/OCF | 4.63 | ||
| P/B | 1.04 | ||
| P/tB | N/A | ||
| EV/EBITDA | 3.64 |
EPS(TTM)-1.13
EYN/A
EPS(NY)-0.91
Fwd EYN/A
FCF(TTM)1.2
FCFY13.22%
OCF(TTM)1.96
OCFY21.59%
SpS15.04
BVpS8.76
TBVpS-1.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -27.82% | ||
| ROE | -65.11% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.82% | ||
| FCFM | 7.99% |
ROA(3y)-107.27%
ROA(5y)-66.14%
ROE(3y)-201.33%
ROE(5y)-123.36%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.28%
GM growth 5Y0.46%
F-Score6
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 7.45 | ||
| Debt/EBITDA | 1.94 | ||
| Cap/Depr | 18.49% | ||
| Cap/Sales | 5.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 66.05% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.73 | ||
| Quick Ratio | 1.69 | ||
| Altman-Z | -5.18 |
F-Score6
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)48.02%
Cap/Depr(5y)40.96%
Cap/Sales(3y)5.44%
Cap/Sales(5y)4.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.71%
EPS Next Y-342.57%
EPS Next 2Y14.84%
EPS Next 3Y10.66%
EPS Next 5Y10.53%
Revenue 1Y (TTM)0.39%
Revenue growth 3Y33.49%
Revenue growth 5Y44.17%
Sales Q2Q%-2.99%
Revenue Next Year-1.69%
Revenue Next 2Y-1.32%
Revenue Next 3Y-0.28%
Revenue Next 5Y1.04%
EBIT growth 1Y6.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year225.4%
EBIT Next 3Y49.56%
EBIT Next 5Y29.08%
FCF growth 1Y217.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y63.32%
OCF growth 3YN/A
OCF growth 5YN/A